TU2218 drug with PD-1 therapy for advanced solid tumors
Treatments studied
Part of Cancer clinical trials.
This Phase 1/2 study tests TU2218 by itself and with PD-1–type immunotherapy (anti–PD-(L)1) in people with advanced solid cancers. It’s designed to find a safe dose and see whether the treatment can shrink tumors when standard options have not worked.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be at least 18 years old and able to sign consent
- You have an advanced solid tumor that can be measured on scans (or, in one part of the study, may not need to be measurable)
- Your general fitness level must be ECOG 0 or 1 (you can usually care for yourself)
- You must be able to swallow capsules and follow study instructions
- Blood, liver, and kidney tests must be within required safety ranges
- Your heart testing must be acceptable (including a normal pumping function and an ECG showing QTcF ≤ 460 ms)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new medication for people with advanced solid tumors that have stopped responding to standard treatments. It aims to see if the drug can shrink tumors or slow their growth.
This phase 1 study tests an investigational drug called HS-20108 in people with advanced solid tumors. It aims to find a safe dose and see how well the drug works against cancer.
This trial studies TU2218 taken with Keytruda (pembrolizumab) in adults with advanced solid cancers that have limited treatment options. The goal is to see if the combination can shrink tumors and is safe enough to keep using.
This Phase 1 trial tests a new drug called IUAb190708 designed to help your immune system fight advanced or recurrent solid cancers. The study will evaluate its safety, how your body handles it, and whether it works against your tumor.
This trial tests a new drug combo (T3011 plus a PD-1/PD-L1 inhibitor) for people with advanced solid tumors that have not responded to other treatments. It aims to see if the combination can shrink tumors or slow their growth.
This trial tests a new pill called TT-702, either alone or with an immunotherapy drug, for people with advanced solid tumors that have stopped responding to standard treatments. The goal is to see if it can help shrink or slow the growth of tumors.
Hear when a new Advanced Solid Tumor trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.